David Gonzalez-de-Olano

Dr. David Gonzalez-de-Olano

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2023 in Allergy
Verified
Journal Article
Closed access
DGDavid Gonzalez-de-Olano
David Gonzalez-de-Olano
PNPaula Navarro-Navarro
Paula Navarro-Navarro
JMJavier I. Muñoz‐González
Javier I. Muñoz‐González
LSLaura Sánchez-Muñoz
Laura Sánchez-Muñoz
AHAna Henriques
Ana Henriques
IÁIván Álvarez-Twose
Iván Álvarez-Twose

25 May 2021 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
CJCristina Jácome
Cristina Jácome
Rute AlmeidaRute Almeida
Rute Almeida
APAna Pereira
Ana Pereira
RARita Amaral
Rita Amaral
Sandra MendesSandra Mendes
Sandra Mendes
JFJoao A. da Fonseca
Joao A. da Fonseca
Background: Poor medication adherence is a major challenge in asthma, and objective assessment of inhaler adherence is needed. The InspirerMundi app aims to monitor adherence while providing a positive experience through gamification and social support. Objective: This study aimed to evaluate the feasibility and acceptability of the InspirerMundi app to monitor medication adherence in adolescents and adults with persistent asthma (treated with daily inhaled medication). Methods: A 1-month mixed method multicenter observational study was conducted in 26 secondary care centers from Portugal and Spain. During an initial face-to-face visit, physicians reported patients’ asthma therapeutic plan in a structured questionnaire. During the visits, patients were invited to use the app daily to register their asthma medication intakes. A scheduled intake was considered taken when patients registered the intake (inhaler, blister, or other drug formulation) by using the image-based medication detection tool. At 1 month, patients were interviewed by phone, and app satisfaction was assessed on a 1 (low) to 5 (high) scale. Patients were also asked to point out the most and least preferred app features and make suggestions for future app improvements. Results: A total of 107 patients (median 27 [P25-P75 14-40] years) were invited, 92.5% (99/107) installed the app, and 73.8% (79/107) completed the 1-month interview. Patients interacted with the app a median of 9 (P25-P75 1-24) days. At least one medication was registered in the app by 78% (77/99) of patients. A total of 53% (52/99) of participants registered all prescribed inhalers, and 34% (34/99) registered the complete asthma therapeutic plan. Median medication adherence was 75% (P25-P75 25%-90%) for inhalers and 82% (P25-P75 50%-94%) for other drug formulations. Patients were globally satisfied with the app, with 75% (59/79) scoring ≥4,; adherence monitoring, symptom monitoring, and gamification features being the most highly scored components; and the medication detection tool among the lowest scored. A total of 53% (42/79) of the patients stated that the app had motivated them to improve adherence to inhaled medication and 77% (61/79) would recommend the app to other patients. Patient feedback was reflected in 4 major themes: medication-related features (67/79, 85%), gamification and social network (33/79, 42%), symptom monitoring and physician communication (21/79, 27%), and other aspects (16/79, 20%). Conclusions: The InspirerMundi app was feasible and acceptable to monitor medication adherence in patients with asthma. Based on patient feedback and to increase the registering of medications, the therapeutic plan registration and medication detection tool were redesigned. Our results highlight the importance of patient participation to produce a patient-centered and engaging mHealth asthma app.

1 January 2013 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
Araceli Díaz-PeralesAraceli Díaz-Perales
Araceli Díaz-Perales
DGDavid Gonzalez-de-Olano
David Gonzalez-de-Olano
Marina Perez-GordoMarina Perez-Gordo
Marina Perez-Gordo
CVCarlos Pastor Vargas
Carlos Pastor Vargas
The prevalence of exotic pet allergies has been increasing over the last decade. Years ago, the main allergy-causing domestic animals were dogs and cats, although nowadays there is an increasing number of allergic diseases related to insects, rodents, amphibians, fish, and birds, among others. The current socio-economic situation, in which more and more people have to live in small apartments, might be related to this tendency. The main allergic symptoms related to exotic pets are the same as those described for dog and cat allergy: respiratory symptoms. Animal allergens are therefore, important sensitizing agents and an important risk factor for asthma. There are 3 main protein families implicated in these allergies, which are the lipocalin superfamily, serum albumin family, and secretoglobin superfamily. Detailed knowledge of the characteristics of allergens is crucial to improvement treatment of uncommon-pet allergies.

1 March 2016 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
DGDavid Gonzalez-de-Olano
David Gonzalez-de-Olano
JMJose M. Morgado
Jose M. Morgado
RJRaquel Juárez-Guerrero
Raquel Juárez-Guerrero
LSLaura Sánchez-Muñoz
Laura Sánchez-Muñoz
JLJavier Letellez-Fernández
Javier Letellez-Fernández
MCMariana C. Castells
Mariana C. Castells

10 July 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
DGDavid Gonzalez-de-Olano
David Gonzalez-de-Olano
IÁIván Álvarez-Twose
Iván Álvarez-Twose
The prevalence of anaphylaxis among patients with clonal mast cell disorders (MCD) is clearly higher regarding general population. Due to a lower frequency of symptoms outside of acute episodes, clonal MCD in the absence of skin lesions might sometimes be difficult to identify which may lead to underdiagnosis, and anaphylaxis is commonly the presenting symptom in these patients. Although the release of mast cell (MC) mediators upon MC activation might present with a wide variety of symptoms, particular clinical features typically characterize MC-mediator release episodes in patients with clonal MCD without skin involvement. Final diagnosis requires a bone marrow study and it is recommended that this should be done in reference centres. In this article, we address the main triggers for anaphylaxis, risk factors, clinical presentation, diagnosis and management of patients with mast cell activation syndromes, with special emphasis on clonal MCAS (systemic mastocytosis and mono(clonal) mast cell activations syndromes).

14 November 2016 in F1000Research
Verified
Journal Article
Open access
PDF file
DGDavid Gonzalez-de-Olano
David Gonzalez-de-Olano
AMAlmudena Matito
Almudena Matito
AOAlberto Orfao
Alberto Orfao
LELuis Escribano
Luis Escribano
Clonal mast cell activation syndromes and indolent systemic mastocytosis without skin involvement are two emerging entities that sometimes might be clinically difficult to distinguish, and they involve a great challenge for the physician from both a diagnostic and a therapeutic point of view. Furthermore, final diagnosis of both entities requires a bone marrow study; it is recommended that this be done in reference centers. In this article, we address the current consensus and guidelines for the suspicion, diagnosis, classification, treatment, and management of these two entities.